38 research outputs found
Higher S2PLIT-UG scores at index admission are associated with a higher functional disease burden and increased biomarkers of myocardial injury and ventricular overload among patients with acutely decompensated heart failure
Goals: Outcomes following acutely decompensated heart failure (ADHF) are poor and associated with
increased mortality and morbidity. Various risk stratification systems have been developed in the past
to predict mortality and rehospitalizations in this population. The S2PLiT-UG score was recently introduced
to stratify ADHF patients in three risk categories in respect to all-cause mortality during
1-year post-discharge period.1 I n t his w ork, w e a imed to d etermine a ssociations o f S 2PLiT-UG score
with functional disease burden estimated by NYHA class and biomarkers including high sensitivity
cardiac troponin I (hs-cTnI), NT-proBNP and C-reactive protein (CRP).
Patients and Methods: A cohort of 106 consecutive ADHF patients enrolled at the Cardiology Department
during 2018-2019 were included in the study. S2PLiT-UG score calculation and laboratory analyses
were performed for each patient at index admission.
Results: Fifty-six (52.8%) patients were designated as low, 24 (22.6%) as intermediate, and 26 (24.6%) as
high risk according to S2PLiT-UG score stratification. Patients significantly differed (p=0.021) in respect
to their NYHA class with mean values of 2.85Ā±0.57, 3.10Ā±0.61, and 3.33Ā±0.56 for low, intermediate, and
high-risk group, respectively. Troponin values were significantly higher in high risk compared to intermediate
and low-risk groups (148.4Ā±72 vs. 68.2Ā±48 vs. 42.2Ā±24 ng/L; p=0.025, respectively). Similarly,
NT-proBNP levels were highest in the high-risk group (13740Ā±7884 pg/mL) followed by intermediate
(7811Ā±5668 pg/mL) and low-risk group (4195Ā±1632 pg/mL), p=0.002. Finally, CRP values differed across
groups with the high-risk group exhibiting highest CRP value (21.8Ā±14.8 mg/L) compared to intermediate
and low-risk group (17.5Ā±15.8 and 12.2Ā±11.3 mg/L, respectively), however, this result was not significant
(p=0.327). S2PLiT-UG score positively correlated with NYHA class (r=0.300, p=0.004), hs-cTnI
(r=0.303, p=0.009), NT-proBNP (r=0.353, p=0.001) and CRP (r=0.203, p=0.069).
Conclusion: Among ADHF patients, higher S2PLiT-UG score values, calculated at index admission, are
associated with higher functional disease burden and increased levels of circulating biomarkers reflecting
myocardial injury and ventricular overload, but not systemic inflammation
UspjeÅ”no lijeÄenje embolije bubrežne arterije Äak 48 sati nakon ispada
Renal artery embolism is a disease that is easily missed due to its infrequent and nonspecific presentations. Although early diagnosis and optimal thrombolytic treatment can sometimes restore renal function, therapeutic guidelines have not yet been established. However, early anticoagulant therapy is beneficial and selective infusion of lytic agents into renal artery has been reported with increasing frequency and efficacy if used in the early stage. We report that intra-arterial thrombolytic therapy with low dose of 35 mg recombinant tissue plasminogen activator (t-PA) may be an effective and safe strategy for the treatment of renal artery embolism, despite the period of ischemia being longer than 48 hours.Embolija bubrežne arterije je bolest koja se lako previdi zbog rijetke pojavnosti i nespecifiÄne prezentacije. Iako rana dijagnoza i optimalno trombolitiÄko lijeÄenje ponekad može vratiti bubrežnu funkciju, terapijske smjernice joÅ” nisu uspostavljene. MeÄutim, rana primjena antikoagulantne terapije je korisna, a o selektivnoj infuziji litiÄkih sredstava u bubrežne arterije, ako se primijeni u ranom stadiju, sve se ÄeÅ”Äe izvjeÅ”Äuje u smislu poveÄanja njene uÄinkovitosti. Mi smo opisali kako intraarterijska trombolitiÄka terapija s niskim dozama od 35 mg rekombinantnog tkivnog aktivatora plazminogena (t-PA) može biti uÄinkovita i sigurna strategija za lijeÄenje embolije bubrežne arterije unatoÄ tomu Å”to je razdoblje ishemije bilo duže od 48 sati
Adropin - potencijalni Äimbenik kardiovaskularne sigurnosti u muÅ”karaca oboljelih od Å”eÄerne bolesti tip 2 lijeÄenih liraglutidom
The aim of this study was to determine plasma adropin concentration and parameters of insulin resistance in obese male type 2 diabetes mellitus (T2DM) patients before and after 3-month liraglutide treatment. In this interventional study, we enrolled 15 obese male T2DM patients with body mass index (BMI) >35 kg/m2, uncontrolled disease and HbA1c >7.5%, having previously taken taking two oral antidiabetic drugs. We modified their therapy to metformin and liraglutide for the next three months. After three months of liraglutide treatment, we observed significant decrease in body weight (from 111.5Ā±18.7 kg to 109.2Ā±17.5 kg, p=0.016) and BMI (from 40.9Ā±7.3 to 40.1Ā±7.0 kg/m2, p=0.021). Plasma adropin concentration increased significantly (p=0.003) compared with baseline. Fasting plasma insulin level decreased from 17.79Ā±6.53 to 13.38Ā±3.51 mU/L (p=0.002), fasting plasma glucose level decreased from 8.66Ā±3.07 to 7.41Ā±2.21 mmol/L (p=0.004) and HbA1c decreased from 7.98Ā±0.70% to 7.26Ā±0.36% (p=0.003). Insulin resistance presented as HOMA-IR decreased significantly from 7.30Ā±5.19 to 4.52Ā±2.61 (p=0.002). Systolic blood pressure, lipid status, liver and kidney function improved, but not reaching statistical significance. Treating obese male T2DM patients with liraglutide resulted in a significantly higher plasma adropin concentration, significant weight loss and improved parameters of insulin resistance, i.e. decreased fasting plasma insulin, plasma glucose levels and HOMA-IR.Cilj je bio usporediti plazmatske vrijednosti adropina i parametre inzulinske rezistencije kod pretilih muÅ”karaca koji boluju od Å”eÄerne bolesti tip 2 (Å BT2) prije i nakon 3 mjeseca primjene liraglutida. U ovoj intervencijskoj studiji sudjelovalo je 15 pretilih muÅ”karaca koji boluju od Å BT2 s indeksom tjelesne mase (ITM) >35 kg/m2, loÅ”e reguliranom boleÅ”Äu i HbA1c >7,5%. Ispitanici su prethodno u terapiji imali dva peroralna antidijabetiÄna lijeka. Nakon ukljuÄenja u studiju terapija im je modificirana na metformin i liraglutid tijekom tri mjeseca. Nakon primjene liraglutida kod ispitanika je zamijeÄeno smanjenje tjelesne mase (sa 111,5Ā±18,7 na 109,2Ā±17,5 kg, p=0,016) i ITM (s 40,9Ā±7,3 na 40,1Ā±7,0 kg/m2, p=0,021), dok su plazmatske vrijednosti adropina bile znaÄajno poviÅ”ene (p=0,003). ZamijeÄeno je sniženje vrijednosti inzulina nataÅ”te (sa 17,79Ā±6,53 na 13,38Ā±3,51 mU/L, p=0,002), glukoze nataÅ”te (s 8,66Ā±3,07 na 7,41Ā±2,21 mmol/L, p=0,004) te HbA1c (sa 7,98Ā±0,70% na 7,26Ā±0,36%, p=0,003). HOMA-IR se znaÄajno smanjio (sa 7,30Ā±5,19 na 4,52Ā±2,61, p=0,002). TakoÄer su
zabilježene niže vrijednosti sistoliÄkog arterijskog tlaka, bolji lipidni profil te poboljÅ”anje jetrene i bubrežne funkcije, iako ne statistiÄki znaÄajno. Primjena liraglutida u pretilih muÅ”karaca koji boluju od Å BT2 rezultira statistiÄki znaÄajno viÅ”im razinama plazmatskog adropina, znaÄajnim smanjenjem tjelesne težine i poboljÅ”anjem svih parametara inzulinske rezistencije, tj. sniženjem plazmatskog inzulina i glukoze nataÅ”te te nižim HOMA-IR
Comparison of the Bond Strengths of Zinc Phosphate, Glass-Ionomer, and Compomere Cement for Dowel Cementation
UnatoÄ dosad mnogim provedenim istraživanjima, ne postoji jedinstvena ocjena koji je cement najbolji za cementiranje konfekcijskih kolÄiÄa. Svrha rada bila je ispitati i usporediti retenciju konfekcijskih kolÄiÄa cementiranih s trima razliÄitim vrstama cemenata: cink-fosfatnim, stakleno-ionomernim i kompomernim.
Prikupljeno je 30 zuba i endodontski preparirano do dubine od 7 mm
i ISO promjera 140. Podijeljeni su u 3 skupine od 10 uzoraka. S pomoÄu triju navedenih vrsta cemenata u njih su cementirani kolÄiÄi od ÄeliÄne žice. PoÅ”to se je cement stvrdnuo, izmjerena je vlaÄna sila potrebna za izvlaÄenje kolÄiÄa iz korijenskoga kanala. Za cink-fosfatni cement iznosila je 175Ā±33,17 N, za stakleno-ionomerni 235,5Ā±46,93 N, a za kompomerni 275,63Ā±96,42 N.
KolÄiÄi cementirani kompomerom imaju znatno jaÄu retenciju od
kolÄiÄa cementiranih cink-fosfatnim ili stakleno-ionomernim cementom. Stakleno-ionomerni cement mnogo jaÄe retinira od cink-fosfatnoga cementa. Prednosti cink-fosfatnog cementa jesu manja osjetljivost na pogrjeÅ”ke u radu i razmjerna jeftinoÄa, te joÅ” uvijek u mnogim kliniÄkim okolnostima ostaje cement izbora.In spite of numerous previous studies, there is no final conclusion on
which type of cement is the best for dowel cementation. The purpose of this study was to compare the retention of dowels cemented with three different cement types: zinc phosphate, glass-ionomer, and compomere.
Thirty teeth were divided into 3 groups, root-canals were prepared
to ISO 140, to 7 mm depth and dowels were cemented. After 40 hours the tensile force needed to dislodge the dowels was recorded. For zinc phosphate it was 175Ā±33.17 N, for glass-ionomer 235.5Ā±46.93 N, and for compomere 275.63Ā±96.42 N.
The dowels cemented with compomere had significantly higher tensile
strength than those cemented with zinc phosphate or glass-ionomer
cement. Glass-ionomer cement had significantly higher tensile strength than zinc phosphate cement. The advantages of zinc-phosphate are its low price and simple usage. Thus, in many clinical situations it may be the cement of choice
Mucositis Grades and Yeast Species
Surgically treated patients with oral, head and neck cancer commonly develop mucositis during additional irradiation therapy. Oral mucosa inflammation other than irradiation is mostly caused by Candida albicans, yeast of Candida genus. This study evaluated possible connection between grades of oral mucositis and oral yeast profile in irradiated patients before, during and after irradiation. In 25 examined patients mucosits grades Ā»0Ā« to Ā»2Ā« before irradiation with
20% positive smears and only two different species of yeasts (C. krusei 4%, C. albicans 16%) during the irradiation changed into Ā»0Ā« to Ā»4Ā« and 36% positive smears with five different species of oral yeasts (C. albicans 12%, C. glabrata 12%, C. parapsilosis 4%, C. guilliermondii 4% and Saccharomyces cerevisiae 4%). Three weeks after irradiation was finished mucositis decreased into Ā»1Ā« to Ā»3Ā« with 20% positive smears and again only two species of yeasts (C. albicans 16%, C. guilliermondii 4%). Mucositis grades was increased significantly (p=0.0037) with changes in fungi profile